These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9052473)

  • 1. The significance of serum alkaline phosphatase bone isoenzyme in prostatic carcinoma with bony metastasis.
    Chen SS; Chen KK; Lin AT; Chang YH; Wu HH; Hsu TH; Chang LS
    Br J Urol; 1997 Feb; 79(2):217-20. PubMed ID: 9052473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen.
    Kataoka A; Yuasa T; Kageyama S; Tsuchiya N; Habuchi T; Iwaki H; Narita M; Okada Y; Yoshiki T
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):480-4. PubMed ID: 16909972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
    Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
    Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
    Desoize B; Amico S; Larbre H; Coninx P; Jardillier JC
    Clin Biochem; 1991 Oct; 24(5):443-6. PubMed ID: 1760884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
    Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase.
    Wymenga LF; Boomsma JH; Groenier K; Piers DA; Mensink HJ
    BJU Int; 2001 Aug; 88(3):226-30. PubMed ID: 11488734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer].
    Wang ZL; Wang XF
    Zhonghua Nan Ke Xue; 2005 Nov; 11(11):825-7. PubMed ID: 16333960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
    Morote J; Lorente JA; Encabo G
    Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis.
    Akimoto S; Furuya Y; Akakura K; Ito H
    Endocr J; 1998 Feb; 45(1):97-104. PubMed ID: 9625452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis.
    Wymenga LF; Groenier K; Schuurman J; Boomsma JH; Elferink RO; Mensink HJ
    BJU Int; 2001 Aug; 88(3):231-5. PubMed ID: 11488735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
    Taue R; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
    Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H
    J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
    Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
    Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].
    Casetta G; Gamba P; Piana P; Pecchio F; Tizzani A
    Minerva Urol Nefrol; 1995 Mar; 47(1):9-12. PubMed ID: 7570264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
    Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
    Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
    Akimoto S; Akakura K; Shimazaki J
    Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer.
    Nguyen-Pamart M; Caty A; Feutrie ML; Fournier C; Gosselin P; Mazeman E
    Br J Urol; 1997 Sep; 80(3):452-5. PubMed ID: 9313666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.